Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults with Hyperlipidemia on Stable Doses of a Statin

- Men and women ages 18 to 70 years (inclusive) at the time of screening with hyperlipidemia - Body mass index (BMI) ≥18 and ≤ 35 kg/m^2 at the time of screening - Low-density lipoprotein cholesterol (LDL-C) level of 70-220 mg/dL (inclusive) at screening as measured by direct assay - For Cohorts 1-5: On a stable dose of rosuvastatin (Crestor) < 40 mg/day, atorvastatin (Lipitor) < 80 mg/day, or simvastatin (Zocor) 20-80 mg/day for ≥ 1 month prior to enrollment and expected to remain on this dose for the remainder of the study - For Cohort 6: On a stable dose of rosuvastatin (Crestor) 40 mg/day or atorvastatin (Lipitor) 80 mg/day for ≥ 1 month prior to enrollment and expected to remain on this dose for the remainder of the study - For Cohort 7: Diagnosis of heterozygous familial hypercholesterolemia, based on a score of ≥ 9 points using the World health Organization (WHO) criteria

- Diagnosis of homozygous familial hypercholesterolemia - History of heart failure, coronary artery bypass graft, or cardiac arrhythmia - History of acute coronary syndrome (e.g. myocardial infarction, hospitalization for unstable angina) or percutaneous coronary intervention, within 12 months prior to enrollment - Planned cardiac surgery or revascularization - Known aortic, peripheral vascular or cerebrovascular disease (including history of stroke or transient ischemic attack) - Diabetes mellitus with any of the following: (a) known microvascular or macrovascular disease (b) HbA1c > 8.0% at screening (c) use of any hypoglycemic medication other than metformin - Uncontrolled hypertension (systolic blood pressure ≥ 150 or diastolic blood pressure ≥ 90 mmHg) either on or off therapy at screening or at baseline